This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of -23.91% and -3.36%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Lineage Cell (LCTX) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Lineage Cell's (LCTX) Q1 earnings call, investor focus will be on its progress with the pipeline candidate OpRegen, currently being developed for treating dry AMD, as well as other pipeline updates.
5 Drug/Biotech Stocks Set to Outpace Q1 Earnings Estimates
by Kinjel Shah
Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.
BorgWarner (BWA) to Post Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Heightening coronavirus fears, along with supply-chain inefficiencies and higher research and development costs, are likely to have clipped BorgWarner's (BWA) margins in Q1.
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Acadia (ACAD) Up 1.1% Since Last Earnings Report?
by Zacks Equity Research
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ACADIA (ACAD) Q4 Earnings Surpass, Nuplazid Drives Sales
by Zacks Equity Research
ACADIA (ACAD) beats on earnings and revenues in the fourth quarter.
Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of 8.11% and 2.57%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
ACADIA (ACAD) Up More Than 100% in the Past Year: Here's Why
by Zacks Equity Research
ACADIA's (ACAD) only marketed drug Nuplazid registers strong sales in 2019. The drug's label expansion efforts also look promising with several studies currently underway for various CNS disorders.
Has ACADIA Pharmaceuticals (ACAD) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ACAD) Outperforming Other Medical Stocks This Year?
Biotech Stock Outlook: M&A Activity Retains Growth Streak
by Ekta Bagri
The biotech sector enjoys a good run in 2019 on the back of the M&A activities and positive pipeline updates underway. We expect this momentum to stay in 2020 as well.
5 Biotech Stocks That Have More Than Doubled This Year
by Ekta Bagri
The biotech sector has had a good run in 2019 on the back of ongoing M&A activities and positive pipeline updates.
The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech
5 Biotech Stocks Up More Than 100% This Year So Far
by Indrajit Bandyopadhyay
The biotech sector recovers on the back of rising M&A activities and pipeline successes in 2019 after a dismal 2018. Here we discuss five biotech companies recording impressive growth.
What Makes Acadia Pharmaceuticals (ACAD) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Acadia Pharmaceuticals (ACAD) have what it takes to be a top stock pick for momentum investors? Let's find out.
Top Ranked Momentum Stocks to Buy for November 25th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 25th.
Medtronic (MDT) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
In the fiscal second quarter, Medtronic (MDT) is expected to have registered strong growth in its ICD and CRT product lines.
The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene
4 Biotech Stocks That Could Keep Beating Wall Street
by Zacks Equity Research
The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.
What Makes Acadia Pharmaceuticals (ACAD) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Acadia Pharmaceuticals (ACAD) have what it takes to be a top stock pick for momentum investors? Let's find out.
Acadia (ACAD) Upgraded to Buy: Here's Why
by Zacks Equity Research
Acadia (ACAD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of 29.27% and 6.79%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Cigna (CI) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Cigna (CI) Q3 earnings are likely to have benefited from higher contribution across all its segments and effect of share buyback.
Teladoc (TDOC) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Teladoc (TDOC) Q3 earning are likely to have benefited from increased membership and visits, and accretive effect of earlier acquisitions.
Will Nuplazid Aid Growth for ACADIA (ACAD) in Q3 Earnings?
by Zacks Equity Research
During ACADIA's (ACAD) third-quarter 2019 conference call, investor focus will be on the sales figure of its only marketed drug Nuplazid and its label expansion studies.